英国英格兰宫颈癌发病率至2040年的预测:四种情景下的模型研究
该模型研究结合人群发病率趋势模型、个体水平数据和微观模拟,预测英格兰至2040年宫颈癌发病率。现状情景下诊断高峰年龄将从2011-15年的25-29岁移至2036-40年的55-59岁;2019年起HPV初筛可使25-64岁年龄标化率到2028年降低19%;九价疫苗较HPV 16/18疫苗可进一步降低36%;若筛查覆盖率降至50%,率可增加27%。
要点
- 现状情景下宫颈癌诊断高峰年龄将从2011-15年的25-29岁移至2036-40年的55-59岁。
- 2019年起HPV初筛可使25-64岁年龄标化率到2028年从15.1降至12.2/10万,降低19%。
- 九价疫苗较持续HPV 16/18疫苗可使25-29岁女性2036-40年率从9.5进一步降至6.1/10万,降低36%。
核心结论
- 未来应关注为已接种疫苗女性提供强度较低的筛查方案,并更多致力于提高未接种疫苗女性的筛查覆盖率及整合新技术以加强现有宫颈筛查。
研究设计与样本
- 数据模型研究,结合人群发病率趋势模型、个体水平数据的广义线性模型和不可观测疾病状态的微观模拟。
- 使用年龄-时期-队列模型估计出生队列效应,并以人群病例对照研究数据(未接种女性)和微观模拟模型(已接种女性)获取按筛查史的相对危险度。
- 按5岁年龄组(25-29岁至75-79岁)和5年时期(2016-20至2036-40)的筛查与疫苗接种史组合比例加权估计人群发病率。
主要发现
- 现状情景下宫颈癌诊断高峰年龄将从2011-15年的25-29岁移至2036-40年的55-59岁,1975-1990年出生的未接种女性终生风险相对较高。
- 2019年起HPV初筛可使25-64岁年龄标化率到2028年从2016年的15.1降至12.2/10万,降低19%。
- 接种HPV 16/18疫苗可使25-29岁女性宫颈癌率从2011-15年的20.9降至2036-40年的9.5/10万,降低55%。
- 2019年起九价疫苗较持续HPV 16/18疫苗可使25-29岁女性2036-40年率从9.5进一步降至6.1/10万,降低36%。
- 1991年前出生女性不直接受益于疫苗,尽管有疫苗和HPV初筛且筛查覆盖率不变,25-79岁欧洲年龄标化率仅从2011-15年的12.8降至2036-40年的11.5/10万,降低10%;若筛查覆盖率降至50%,率可从12.8增至16.3/10万,增加27%。
关键数值与推荐
- HPV初筛的相对危险度相对于细胞学筛查。
- 筛查史分类为从未筛查、定期筛查和失访者。
- 九价疫苗情景为2019年起引入,与持续HPV 16/18疫苗接种比较。
- 筛查覆盖率降至50%的情景下欧洲年龄标化率从12.8增至16.3/10万。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the next 25 years, the epidemiology of cervical cancer in England, UK, will change: human papillomavirus (HPV) screening will be the primary test for cervical cancer. Additionally, the proportion of women screened regularly is decreasing and women who received the HPV vaccine are due to attend screening for the first time. Therefore, we aimed to estimate how vaccination against HPV, changes to the screening test, and falling screening coverage will affect cervical cancer incidence in England up to 2040. METHODS: We did a data modelling study that combined results from population modelling of incidence trends, observable data from the individual level with use of a generalised linear model, and microsimulation of unobservable disease states. We estimated age-specific absolute risks of cervical cancer in the absence of screening (derived from individual level data). We used an age period cohort model to estimate birth cohort effects. We multiplied the absolute risks by the age cohort effects to provide absolute risks of cervical cancer for unscreened women in different birth cohorts. We obtained relative risks (RRs) of cervical cancer by screening history (never screened, regularly screened, or lapsed attender) using data from a population-based case-control study for unvaccinated women, and using a microsimulation model for vaccinated women. RRs of primary HPV screening were relative to cytology. We used the proportion of women in each 5-year age group (25-29 years to 75-79 years) and 5-year period (2016-20 to 2036-40) who have a combination of screening and vaccination history, and weighted to estimate the population incidence. The primary outcome was the number of cases and rates per 100 000 women under four scenarios: no changes to current screening coverage or vaccine uptake and HPV primary testing from 2019 (status quo), changing the year in which HPV primary testing is introduced, introduction of the nine-valent vaccine, and changes to cervical screening coverage. FINDINGS: The status quo scenario estimated that the peak age of cancer diagnosis will shift from the ages of 25-29 years in 2011-15 to 55-59 years in 2036-40. Unvaccinated women born between 1975 and 1990 were predicted to have a relatively high risk of cervical cancer throughout their lives. Introduction of primary HPV screening from 2019 could reduce age-standardised rates of cervical cancer at ages 25-64 years by 19%, from 15·1 in 2016 to 12·2 per 100 000 women as soon as 2028. Vaccination against HPV types 16 and 18 (HPV 16/18) could see cervical cancer rates in women aged 25-29 years decrease by 55% (from 20·9 in 2011-15 to 9·5 per 100 000 women by 2036-40), and introduction of nine-valent vaccination from 2019 compared with continuing vaccination against HPV 16/18 will reduce rates by a further 36% (from 9·5 to 6·1 per 100 000 women) by 2036-40. Women born before 1991 will not benefit directly from vaccination; therefore, despite vaccination and primary HPV screening with current screening coverage, European age-standardised rates of cervical cancer at ages 25-79 years will decrease by only 10% (from 12·8 in 2011-15 to 11·5 per 100 000 women in 2036-40). If screening coverage fell to 50%, European age-standardised rates could increase by 27% (from 12·8 to 16·3 per 100 000 by 2036-40). INTERPRETATION: Going forward, focus should be placed on scenarios that offer less intensive screening for vaccinated women and more on increasing coverage and incorporation of new technologies to enhance current cervical screening among unvaccinated women. FUNDING: Jo's Cervical Cancer Trust and Cancer Research UK.
引用
- Castanon A, Landy R, Pesola F, et al. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. Lancet Public Health. 2017. PMID: 29307386. doi:10.1016/S2468-2667(17)30222-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。